Songling Xuemaikang Capsule (松龄血脉康胶囊) for primary hypertension: A systematic review of randomized controlled trials

Objective To evaluate the effectiveness and safety of Songling Xuemaikang Capsule (松龄血脉康胶囊, SXC) for the treatment of primary hypertension. Methods An extensive search including Cochrane Library, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of integrative medicine 2015-04, Vol.21 (4), p.312-320
Main Authors: Yang, Xiao-chen, Xiong, Xing-jiang, Yang, Guo-yan, Wang, He-ran, Wang, Jie
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
Capsules
Drugs, Chinese Herbal - administration & dosage
Drugs, Chinese Herbal - therapeutic use
Essential Hypertension
Evidence-Based Integrative Medicine
Female
Humans
Hypertension - drug therapy
Hypertension - epidemiology
Male
Medicine
Medicine & Public Health
Middle Aged
Randomized Controlled Trials as Topic - statistics & numerical data
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To evaluate the effectiveness and safety of Songling Xuemaikang Capsule (松龄血脉康胶囊, SXC) for the treatment of primary hypertension. Methods An extensive search including Cochrane Library, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), KoreaMed, Japanese database, and online clinical trial registry websites was performed up to February 2013. Randomized controlled trials (RCTs) regarding SXC for the treatment of primary hypertension were searched without no language restrictions. The quality of each trial was assessed according to the Cochrane Reviewers’ Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration. Result A total of 17 RCTs involving 1,778 patients were included. Meta-analysis showed that there was no significant difference between SXC and antihypertensive agents on systolic blood pressure [mean difference (MD): −0.10 [−4.83, 4.63]; P =0.97] and diastolic blood pressure (MD: 1.00 [−1.16, 3.16]; P =0.36), but SXC combined with antihypertensive drugs was more effective in lowering systolic blood pressure (MD: −6.17 [−7.86, −4.49]; P
ISSN:1672-0415
1993-0402
DOI:10.1007/s11655-014-1709-6